SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1476 5381
 

Sökning: L773:1476 5381 > Animal modeling of ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003527naa a2200493 4500
001oai:DiVA.org:uu-146230
003SwePub
008110215s2011 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1462302 URI
024a https://doi.org/10.1111/j.1476-5381.2010.01163.x2 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Marklund, Niklasu Uppsala universitet,Neurokirurgi4 aut0 (Swepub:uu)niklmark
2451 0a Animal modeling of traumatic brain injury in pre-clinical drug development :b where do we go from here?
264 c 2012-02-09
264 1b Wiley,c 2011
338 a print2 rdacarrier
520 a Traumatic brain injury (TBI) is the leading cause of death and disability in young adults. Survivors of TBI frequently suffer from long term personality changes and deficits in cognitive and motor performance, urgently calling for novel pharmacological treatment options. To date, all clinical trials evaluating neuroprotective compounds have failed in demonstrating clinical efficacy in cohorts of severely injured TBI patients. The purpose of the present review is to describe the utility of animal models of TBI for pre-clinical evaluation of pharmacological compounds. No single animal model can adequately mimic all aspects of human TBI owing to the heterogeneity of clinical TBI. To successfully develop compounds for clinical TBI, a thorough evaluation in several TBI models and injury severities is crucial. Additionally, brain pharmacokinetics and the time window must be carefully evaluated. Although the search for a single-compound, "silver bullet" therapy is ongoing, a combination of drugs targeting various aspects of neuroprotection, neuroinflammation and regeneration may be needed. In summary, finding drugs and prove clinical efficacy in TBI is a major challenge ahead for the research community and the drug industry. For a successful translation of basic science knowledge to the clinic to occur we believe that a further refinement of animal models and functional outcome methods is important. In the clinical setting, improved patient classification, more homogenous patient cohorts in clinical trials, standardized treatment strategies, improved CNS drug delivery systems and monitoring of target drug levels and drug effects is warranted.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng
653 a Traumatic brain injury
653 a review
653 a neuroprotection
653 a magnesium
653 a yclosporin
653 a glutamate
653 a reactive oxygen species
653 a inflammation
653 a plasticity
653 a animal modeling
653 a contusion
653 a Neurosurgery
653 a Neurokirurgi
653 a Neurosurgery
653 a Neurokirurgi
700a Hillered, Larsu Uppsala universitet,Neurokirurgi4 aut0 (Swepub:uu)larshill
710a Uppsala universitetb Neurokirurgi4 org
773t British Journal of Pharmacologyd : Wileyg 164:4, s. 1207-1229q 164:4<1207-1229x 0007-1188x 1476-5381
856u https://europepmc.org/articles/pmc3229758?pdf=render
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-146230
8564 8u https://doi.org/10.1111/j.1476-5381.2010.01163.x

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Marklund, Niklas
Hillered, Lars
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Kirurgi
Artiklar i publikationen
British Journal ...
Av lärosätet
Uppsala universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy